(ČIA) The European Medicines Agency (EMA) has launched an ongoing evaluation of the Sputnik V anti-COVID-19 vaccine. The vaccine was developed by the Russian Institute of Epidemiological and Microbiological Research in Moscow. The applicant in the EU will be R-Pharm Germany. Irena Storová, director of the State Institute for Drug Control (SÚKL), said that the interim evaluation would show whether the data from the Russian clinical study were at a sufficient level to ask the EMA to evaluate the vaccine when applying for registration. The information was published by SÚKL.